Stay updated with breaking news from Clinical Development Plan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
R&D Day on December 14 to provide clinical updates for BT8009, BT5528 and BT7480, and highlight broad capabilities of novel Bicycle® technology Alignment with FDA on expedited development and...
Company's cash and cash equivalents stand at $572.1 million as of September 30, 2023
Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% and mPFS of 5.0...
Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical...
Medical Director, Oncology - Early Development in Full time, Director, Biomedicine with Adveritas - F. Hoffmann la Roche. Apply Today.